Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Neurodegenerative Disease Market Value Growth And Long-Term Outlook
The neurodegenerative disease market size has experienced significant expansion in recent years. It is projected to grow from $57.23 billion in 2025 to $62.59 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.4%. The drivers of this historical growth encompass a limited understanding of disease pathology, a reliance on conventional symptomatic treatments, an expanding aging population, an increasing healthcare infrastructure dedicated to neurology, and the restricted availability of advanced diagnostic tools.
The neurodegenerative disease market is anticipated to observe significant expansion in the foreseeable future. It will grow to $88.5 billion in 2030 at a compound annual growth rate (CAGR) of 9.0%. This projected growth during the forecast period is primarily driven by advancements in gene and cell therapy, heightened research and development into novel neuroprotective drugs, an expansion of clinical trial networks, the integration of AI for earlier diagnosis and patient monitoring, and the increasing adoption of personalized medicine approaches. Noteworthy trends expected in this period include the rising occurrence of neurodegenerative disorders, increased investment in drug development and clinical trials, the adoption of targeted and personalized therapeutic methods, an increase in awareness and early diagnosis programs, and the expansion of home-based and outpatient care solutions.
Get A Free Sample Report With In-Depth Market Insights:
Neurodegenerative Disease Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
Enhanced activity in research and clinical trials is projected to fuel the expansion of the neurodegenerative disease market in the future. These trials are investigative studies involving human subjects, designed to assess the safety, effectiveness, and potential adverse reactions of novel therapies, medications, or medical instruments. The surge in such research endeavors and trials is largely due to the growing need for innovative treatments to meet changing healthcare demands and improve patient health outcomes. Clinical trials are instrumental in advancing neurodegenerative disease research by supplying essential information regarding the safety and efficacy of new treatments, thereby contributing to therapeutic progress and better patient results. A notable illustration of this trend is found in a report from December 2024 by the UK-based Association of the British Pharmaceutical Industry (ABPI), which indicated a 3.7% increase in new UK industry clinical trials initiated in 2023 compared to 2022. Consequently, the heightened volume of research and clinical trials is anticipated to stimulate the growth of the neurodegenerative disease market.
Neurodegenerative Disease Market Segment Trends And Revenue Contributors
The neurodegenerative disease market covered in this report is segmented –
1) By Disease Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Amyotrophic Lateral Sclerosis
2) By Drug Type: N-methyl-D-aspartate Receptor antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Acetylcholinesterase (AChE) Inhibitors, Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitor, Selective Serotonin Reuptake Inhibitor (SSRIs), Other Drug Types
3) By Route of Administration: Oral, Injectable, Transdermal, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
5) By End-User: Hospital, Retail, Online
Subsegments:
1) By Parkinson’s Disease: Idiopathic Parkinson’s Disease, Familial Parkinson’s Disease, Early-Onset Parkinson’s Disease, Parkinsonism
2) By Alzheimer’s Disease: Early-Onset Alzheimer’s Disease, Late-Onset Alzheimer’s Disease, Familial Alzheimer’s Disease (FAD), Inflammatory Subtype, Non-Inflammatory Subtype, Cortical Subtype
3) By Multiple Sclerosis (MS): Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS), Progressive-Relapsing MS (PRMS)
4) By Huntington’s Disease: Adult-Onset Huntington’s Disease, Juvenile Huntington’s Disease
5) By Amyotrophic Lateral Sclerosis (ALS): Classical ALS, Limb-Onset ALS, Bulbar-Onset ALS, Respiratory-Onset ALS, Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), Juvenile ALS, ALS-Parkinsonism-Dementia Complex (ALS-PDC)
Neurodegenerative Disease Market Innovation Trends Shaping Future Development
Key companies in the neurodegenerative disease market are prioritizing the development of innovative products, such as next-generation adaptive Deep Brain Stimulation (aDBS) systems, with the goal of improving treatment precision, enhancing disease-modifying effects, and elevating patient quality of life. These advanced neurostimulation devices, known as next-generation adaptive deep brain stimulation (aDBS) systems, are engineered to provide real-time, personalized treatment for Parkinson’s disease by dynamically adjusting stimulation parameters based on neural feedback, thereby optimizing therapeutic effects and minimizing side effects for improved patient outcomes. For instance, in February 2025, Medtronic, a US-based medical technology company, secured approval from the U.S. Food and Drug Administration (USFDA) for the world’s first adaptive deep brain stimulation (aDBS) system tailored for Parkinson’s disease. This approval specifically covers the premarket approval (PMA) application for the Percept RC neurostimulator with BrainSense technology, designed to automatically adapt therapy in response to a patient’s unique brain signals. The system has been clinically validated to offer symptom relief for patients with advanced Parkinson’s disease and signifies a major leap in personalized neuromodulation therapies.
Neurodegenerative Disease Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the neurodegenerative disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Biogen Inc., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics Inc., Voyager Therapeutics Inc., AC Immune SA, Amylyx Pharmaceuticals Inc., Sage Therapeutics Inc., Alzheon Inc.
View The Full Neurodegenerative Disease Market Report:
Neurodegenerative Disease Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the neurodegenerative disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurodegenerative disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model